PT  - JOURNAL ARTICLE
AU  - Alfuwayris, Jumanah J.
AU  - Almulhim, Amal M.
AU  - Almansour, Mohammed A.
AU  - Albadi, Marzouq A.
AU  - Alhomood, Ibrahim A.
AU  - Alblewi, Faisal
AU  - Althemery, Abdullah U.
TI  - Common clinical pattern of antineutrophil cytoplasmic antibody -associated vasculitis
AID  - 10.15537/smj.2023.44.5.20220818
DP  - 2023 May 01
TA  - Saudi Medical Journal
PG  - 486--491
VI  - 44
IP  - 5
4099  - http://smj.org.sa/content/44/5/486.short
4100  - http://smj.org.sa/content/44/5/486.full
SO  - Saudi Med J2023 May 01; 44
AB  - Objectives: To understand the most common type and clinical manifestations of associated vasculitis (AAV) in the Saudi Arabia.Methods: This retrospective study was conducted at King Fahad Medical City and the Security Forces Hospital Program, Riyadh, Saudi Arabia, between January 2014 and May 2022. Patients aged ≥18 years were included in the study and diagnosed based on clinical manifestations, serology, or histopathology according to the EMA algorithm. Univariate analysis was carried out to compare different groups; a series of independent samples t-tests was applied for continuous data.Results: A total of 53 patients were enrolled: eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). Overall, proteinase-3 was the most prevalent (52.8%), and myeloperoxidase, myeloperoxidase MPO was the least prevalent antineutrophil cytoplasmic antibody (ANCA)-type (18.9%) among patients; other patients showed negative ANCA test results. The clinical manifestations differed significantly between EGPA and GPA groups in pulmonary, neurological, cardiological, and renal signs and symptoms (p<0.05); there was a higher incidence of the former 3 in the EGPA group. Although upper airway was predominant in all groups, there was no statistical difference between both groups.Conclusion: This study validated international reports on AAV clinical manifestations in the Saudi population. The GPA was associated with more upper airway and pulmonary signs and symptoms. Further investigation is needed to understand the treatments and quality of life of patients with AAV.